Replies to post #169365 on Biotech Values

[genisi]

Do you think 8-weeks of Sofo/Ledi would show superior SVR rates to 12-weeks of Sofo/Ledi in GT1A patients within a large study (n=600)?

I certainly have not written off the possibility that GILD's 8-weeks regimen would be non inferior to a 12-weeks one. Riba sparing plus only 8 weeks seems too much of a stretch, but the real option might be as mentioned before - 8 weeks with Riba vs 12 weeks without. In this case I don't expect the shorter duration treatment to have a meaningful commercial advantage unless other DAA regimens would include Riba.